Table 2.

Co-Maneuvers Used in Randomized Controlled Trials

Co-maneuver Types	Co-maneuver Characteristics by Study (Indicated by Reference Number)
Frequency of clinic visits	Frequent baseline visits: 18, 22–31, 35, 36, 38	Every 3 to 4 months: 18–20, 25, 27, 29, 33, 34, 37	Every 6 months: 22–24, 26, 28, 30–32, 35, 36	Annual follow-up only: 38
Activities occurring at each visit	Treatment titrated unless BP at target: 18–37	BP measured and compared to target: 18–38	Assessment of study endpoints: 18–38
Feedback given to study clinicians	Detailed feedback and decision support: 38	Structured reminders of participants’ status: 20, 30, 33, 34	No additional structured decision support: 18, 19, 22–28, 32, 35–37
Education offered to study participants	Counseling, support, and behavior modification education: 37, 38	Structured education at follow-up visits: 18, 21	No structured education: 19, 22–36
Specificity of blood pressure target(s)	A specific systolic and/or diastolic BP target: 18, 20–38	Targeted BP change from baseline: 19, 25, 27, 31
Action plan for modification of treatments	Action plan explicitly defined: 18–37	Specific medications or medication classes: 18–38
Communication of adverse events from principal maneuver	Adverse events discussed at each follow-up: 18–37	Specific adverse events queried: 19, 20–27, 29, 30, 32–37	No published documentation of adverse events: 38

BP, blood pressure.